[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results].
Soyka
M
M
Psychiatrische Klinik, Universität München.
Zieglgänsberger
W
W
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use*; D000437:Alcoholism / Q000534:rehabilitation*; D000818:Animals; D001921:Brain / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D011963:Receptors, GABA-A / Q000187:drug effects*; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects*; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000427:Alcohol Deterrents; D011963:Receptors, GABA-A; D016194:Receptors, N-Methyl-D-Aspartate; D013654:Taurine; D000077443:Acamprosate